Why Is Merck Stock Trading Higher On Monday?
Why Is Merck Stock Trading Higher On Monday?
On Monday, Merck & Co Inc (NYSE:MRK) revealed topline results from the Phase 3 ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality.
週一，默沙東公司（紐交所：MRK）公佈了評估Winrevair（sotatercept-csrk）在高風險死亡的成人肺動脈高壓（PAH，WHO 1組）功能分類（FC）III或IV患者中的第3期ZENITH研究的頂線結果。
PAH is high blood pressure in pulmonary arteries, which carry oxygen-poor blood from the heart to the lungs.
PAH是肺動脈的高血壓，這種動脈將缺氧血液從心臟輸送到肺部。
ZENITH met its primary endpoint of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening-related hospitalization of ≥ 24 hours).
ZENITH達到了首次發病或死亡事件（所有原因的死亡、肺移植或與PAH惡化有關的住院≥ 24小時）的主要終點。
Also Read: Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
另請閱讀：默沙東的Gardasil疫苗面臨持續的挑戰，分析師對新批准的用於罕見肺病的sotatercept表示樂觀。
In the study, Winrevair demonstrated a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo, on top of background PAH therapy.
在研究中，Winrevair相較於安慰劑顯示出在背景PAH治療基礎上，顯著降低了發病或死亡事件的風險，並且具有臨床意義。
An independent data monitoring committee has recommended that ZENITH be stopped early and that all participants be offered the opportunity to receive Winrevair through the SOTERIA open-label extension study.
一獨立數據監測委員會建議提前停止ZENITH研究，併爲所有參與者提供通過SOTERIA開放標籤擴展研究接受Winrevair的機會。
In the preliminary assessment, adverse events and serious adverse events were balanced between the treatment groups.
在初步評估中，治療組之間的不良事件和嚴重不良事件均衡。
Winrevair is currently approved in the U.S. and 36 countries based on the Phase 3 STELLAR trial results.
Winrevair目前在美國和36個國家獲得批准，基於第3期恒星幣試驗結果。
In March, the FDA approved Winrevair for injection for adults with pulmonary arterial hypertension (PAH) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.
在三月，FDA批准了Winrevair注射劑用於治療成年肺動脈高壓（PAH），以增加運動能力，提高WHO功能等級（FC），並降低臨床惡化事件的風險。
Most recently, in November of this year, WINREVAIR was submitted for approval in Japan based on the STELLAR trial and results from an open-label Phase 3 study in Japanese patients.
最近在今年十一月，WINREVAIR已經基於恒星幣試驗和在日本患者的開放標籤三期研究結果提交了在日本的批准申請。
Price Action: MRK stock is up 1.93% at $101.09 at last check Monday.
價格行動：默沙東的股票在週一最後檢查時上漲了1.93%，報101.09美元。
- Nvidia Unveils Fugatto: AI Tool That Transforms Sound Creation For Music, Ads, And Gaming
- 英偉達推出Fugatto：一款爲音樂、廣告和arvr遊戲轉變音效創作的人工智能工具
Image via Pixabay.
圖片來源於Pixabay.
譯文內容由第三人軟體翻譯。
